GC Green Cross to Invest 530 Billion Won in Ochang Plant... Establishes Dedicated SCIG Production Line

Top Priority Pipeline: "20% SCIG"
Aiming to Submit IND for U.S. Phase 3 Clinical Trials Next Year

GC Green Cross is set to accelerate the establishment of infrastructure for subcutaneous immunoglobulin (SCIG) injections in the United States.

GC Green Cross announced on July 16 that it had signed a memorandum of understanding (MOU) for mid- to long-term investment in Cheongju with North Chungcheong Province and Cheongju City at the North Chungcheong Provincial Government office.

GC Green Cross Headquarters, Yongin, Gyeonggi Province. GC Green Cross

GC Green Cross will invest a total of 530 billion won in the Ochang plant over the next eight years, up to 2033. Of this amount, 140 billion won will be allocated to establishing production facilities for '20% SCIG (GC5136B)'. The 20% SCIG is one of the five top-priority pipeline projects recently selected by the company.

Based on its optimized processes, GC Green Cross aims to submit an Investigational New Drug (IND) application for phase 3 clinical trials of the 20% SCIG—which is currently at the preclinical stage—to the U.S. Food and Drug Administration (FDA) next year.

Euncheol Huh, CEO of GC Green Cross, stated, "This investment is a significant decision that builds on the achievements of Aligloly, which successfully entered the U.S. market. Through close cooperation with local governments, we will expand high-value-added production infrastructure and continuously enhance our competitiveness in the plasma fractionation sector."

This content was produced with the assistance of AI translation services.